Authors' recommendations: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. IBD is commonly divided into 2 subtypes: Crohn's disease (CD) and ulcerative colitis (UC). IBD has the potential to cause damage to the bowel in the form of inflammation and ulcers, making it pathologically distinct from other gastrointestinal disorders such as irritable bowel syndrome. It is estimated that approximately 10% to 20% of the global population have symptoms of IBD, with 30% of people seeking physician treatment for IBD symptoms. With no established reference standard for IBD diagnosis and subsequent CD and UC diagnoses, clinical findings, such as: patient history, physical examinations, endoscopy, sigmoidoscopy and/or colonoscopy, are used to determine disease status. Established biomarkers and diagnostic tests that identify IBD and distinguish subtypes could provide an alternative to traditional diagnostic factors and may aid with diagnosis and classification. This report reviews 1 such test, the Prometheus IBD sgi Diagnostic.

Project Status: Completed

Year Published: 2017

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=60926

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc